![]() |
市场调查报告书
商品编码
1499422
全球肠道疾病检测市场:按产品、疾病类型、诊断技术和检测地点 - 预测(2024-2030)Enteric Disease Testing Market by Product (Consumables, Kits, Reagents), Disease Type (Bacterial, Parasitic, Viral), Diagnostic Techniques, Testing Site - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年全球肠道疾病检测市场规模为43.1亿美元,2024年达45.4亿美元,2030年达62.6亿美元,复合年增长率为5.47%。
肠道疾病检测包括各种诊断程序,旨在识别影响胃肠道感染的感染疾病。随着肠道疾病的全球流行、诊断技术、意识和医疗保健支出的进步,对肠道疾病检测的需求持续增长,因为早期和准确的诊断在管理和预防此类疾病的传播方面发挥关键作用。然而,他们面临着挑战,例如与先进测试技术相关的高成本、资源匮乏环境中的访问受限以及需要熟练人员来执行和解释测试。为了解决这些问题,人们持续专注于开发具有成本效益且易于使用的诊断解决方案,这些解决方案可以广泛部署,包括在资源有限的环境中。分子诊断、就地检验以及人工智慧和机器学习的应用相结合,提高检测的准确性和速度,预计将使检测程式多样化。
主要市场统计 | |
---|---|
基准年[2023] | 43.1亿美元 |
预计年份 [2024] | 45.4亿美元 |
预测年份 [2030] | 62.6亿美元 |
复合年增长率(%) | 5.47% |
区域洞察
在强大的医疗保健系统和高昂的医疗成本的推动下,美洲,特别是美国和加拿大,先进诊断解决方案的采用率很高,包括分子诊断和就地检验。该地区的公司享有有利的法规环境和大量的研发投资,使他们能够快速创新并生产肠道疾病检测解决方案。在亚太地区,由于人们对霍乱和伤寒等疾病的认识不断提高以及医疗费用不断上涨,对肠道疾病诊断的需求不断增加。然而,这个市场的特点是先进和传统诊断方法的混合,并且各国之间的医疗基础设施存在显着差异。亚太地区的生产正在扩大,当地企业与成熟的全球企业一起崛起。欧洲、中东和非洲是多样化的,西欧市场高度发达,采用了尖端的诊断技术,而非洲和中东的一些国家获得肠道疾病检测的机会有限,我们正在解决与采购和检测相关的问题。方便。欧洲、中东和非洲的法规环境差异很大,影响了新技术的采用速度。在欧洲、中东和非洲运营的公司平衡技术创新和具有成本效益的生产,以满足不同患者群体的需求。
FPNV定位矩阵
FPNV定位矩阵对于评估供应商在肠道疾病检测市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检查了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对肠道疾病检测市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该领域竞争性质的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对当前肠道疾病检测市场地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[198 Pages Report] The Enteric Disease Testing Market size was estimated at USD 4.31 billion in 2023 and expected to reach USD 4.54 billion in 2024, at a CAGR 5.47% to reach USD 6.26 billion by 2030.
Enteric disease testing encompasses a variety of diagnostic procedures aimed at identifying pathogens that cause infectious diseases affecting the gastrointestinal tract. Given the critical role of early and accurate diagnosis in managing and preventing the spread of these diseases, the need for enteric disease testing is driven by factors such as the growing global prevalence of enteric diseases, advancements in diagnostic technologies, and increased awareness and healthcare spending. However, the practice faces challenges such as the high costs associated with advanced testing technologies, limited accessibility in low-resource settings, and the need for skilled personnel to conduct and interpret tests. To address these issues, there is an ongoing focus on developing cost-effective and user-friendly diagnostic solutions that can be deployed widely, including in resource-constrained environments. The integration of molecular diagnostics, point-of-care testing, and the application of artificial intelligence and machine learning to improve test accuracy and speed is expected to diversify the testing procedures.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 4.31 billion |
Estimated Year [2024] | USD 4.54 billion |
Forecast Year [2030] | USD 6.26 billion |
CAGR (%) | 5.47% |
Regional Insights
In the Americas, especially the United States and Canada, there is a high adoption rate of advanced diagnostic solutions, including molecular diagnostics and point-of-care testing, driven by robust healthcare systems and high healthcare expenditure. Companies in this region benefit from a conducive regulatory environment and significant investment in R&D, leading to rapid innovation and production of enteric disease testing solutions. The APAC region has a growing demand for enteric disease diagnostics due to increasing awareness of diseases such as cholera and typhoid coupled with rising healthcare spending. However, the market is characterized by a mix of advanced and traditional diagnostic practices, with significant variations in healthcare infrastructure across countries. Production in APAC is growing, with local companies emerging alongside established global players. EMEA presents a diverse picture, with highly developed markets in Western Europe employing cutting-edge diagnostic technologies while countries in Africa and parts of the Middle East grapple with challenges related to access and affordability of enteric disease testing. Regulatory environments across EMEA vary widely, affecting the pace of adoption of new technologies. Companies operating in EMEA are balancing innovation with cost-effective production to meet the needs of a diverse patient population.
Market Insights
The market dynamics represent an ever-changing landscape of the Enteric Disease Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Enteric Disease Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Enteric Disease Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Clears MeMed BV Direct from Whole Blood
MeMed announced that its innovative MeMed BV test, designed for rapid differentiation between bacterial and viral infections, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for whole blood samples. This significant milestone allows healthcare professionals to leverage the MeMed Key analyzer, a leading-edge point-of-care device, to diagnose infections accurately in as little as 15 minutes. This breakthrough underscores MeMed's commitment to advancing host response technology and improving patient care by enabling timely and precise treatment decisions. [Published On: 2023-07-19]
Avacta Acquires European Diagnostic Test Maker
Avacta Group, a notable entity in the biotechnology sector, strategically expanded its portfolio by acquiring Coris Bioconcept SRL, a distinguished European producer of rapid diagnostic test kits. Coris Bioconcept specializes in developing, manufacturing, and commercializing lateral flow tests primarily intended for use by healthcare professionals. The company boasts a robust global distribution network, reaching markets across Europe, Asia, South America, Africa, and Oceania, enhancing its presence and operational reach in diagnostic testing. [Published On: 2023-06-01]
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Merck, internationally known as MSD, announced its strategic move to acquire Prometheus Biosciences, Inc., a company in the biotechnological realm focusing on precision medicine methodologies for immune-mediated diseases. This acquisition set the transaction at an impressive total equity value of around USD 10.8 billion. Prometheus, recognized for its innovative approach to developing therapeutic and companion diagnostic solutions, is currently in the clinical stage. This partnership underscores Merck's commitment to advancing healthcare solutions by integrating cutting-edge technology and scientific research into its comprehensive portfolio. [Published On: 2023-04-16]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Enteric Disease Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Enteric Disease Testing Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Abbott Laboratories, Als Limited, Asure Quality, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerica Inc., bioMerieux SA, Bureau Veritas Group, Cepheid Inc., Coris BioConcept SPRL, DiaSorin, Eurofins Scientific SE, Hardy Diagnostics, Intertek Group PLC, Merck & Co., Inc., Merck KGAA, Meridian Bioscience Inc., Merieux NutriSciences Corporation, Neogen Corporation, Nova Biologicals, Perkinelmer, Inc., Qiagen N.V., Quest Diagnostics, Romer Labs Division Holding GmbH, SGS SA, Symbio Laboratories, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and TUV SUD AG.
Market Segmentation & Coverage